

EPHMRA
ANATOMICAL CLASSIFICATION
GUIDELINES 2018

Section A

Changed Classes/Guidelines: Changes Highlighted

Final Version

Date of issue: 15th December 2017

A2	ANTACIDS, ANTIFLATULENTS AND ANTI-ULCERANTS	
A2A	ANTACIDS, ANTIFLATULENTS, CARMINATIVES	
A2A1	Plain antacids Includes combinations of two or more antacid substances as well as skimmed-milk powder and milk complexes with pure antacid combinations. Stomach teas are classified in A2X€. Includes combinations with alginic acid. Alka Seltzer is classified in N2B when it contains an analgesic. If it contains only an antacid, it is classified here.	R1997 r2018
A2A2	Plain antiflatulents and carminatives This group includes mainly dimethicone/simethicone (dimethylpolysiloxane, DMPS) preparations. Carminatives and herbal combinations are classified in A2A7 except carminatives with a choloretic or cholagogue effect which are classified in A5A. Dimethicone/simethicone preparations with enzymes are classified in A9A.	R1994
A2A3	Antacids with antispasmodics Distinguishing between antispasmodics and ulcer therapy is often difficult but products with a substance with known antispasmodic properties are included in this group.	
A2A4	Antacids with antiflatulents or carminatives Includes combinations of plain antacids with antiflatulents or carminatives.	
A2A5	Antacids with antiflatulents and/or carminatives and antispasmodics Products in this group should contain an antacid and an antispasmodic together with an antiflatulent or a carminative or both.	
A2A6	Antacids with other drugs Includes antacid combinations other than those classified in A2A3, A2A4 and A2A5. Specific anti-ulcerants are classified in A2B. Alka-Seltzer is classified in N2B or A2A1. Combinations of low dose H2 antagonists with antacids are classified here.	R2002
A2A7	Antiflatulents and/or carminatives with other drugs Includes all antiflatulents and/or carminative combinations not included in A2A4, A2A5, A9A. Combinations of antispasmodics with antiflatulents are classified in A3E.	r2011

A2B	ANTIULCERANTS Combinations of specific antiulcerants with anti-infectives against <i>Helicobacter pylori</i> are classified according to the anti-ulcerant substance. For example, proton pump inhibitors in combination with these anti-infectives are classified in A2B2.	r2016
A2B1	H2 antagonists Includes, for example, cimetidine, famotidine, nizatidine, ranitidine, roxatidine. Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6.	R2002
A2B2	Proton pump inhibitors Includes esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole.	r2016
A2B3	Prostaglandin antiulcerants Includes misoprostol, enprostil.	
A2B4	Bismuth antiulcerants Includes combinations with antacids.	
A2B9	All other antiulcerants Includes all other products specifically stated to be antiulcerants even when containing antispasmodics (see A3). Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6. Included are, eg carbenoxolone, gefarnate, pirenzepine, proglumide, sucralfate and sofalcone. Herbal combinations are classified in A2X <u>C</u> . In Japan, Korea and Taiwan only, sulphuride and other psycholeptics indicated for ulcer use are also included in this group, whilst in all other countries, these compounds are classified in N5A9. Products containing rebamipide for gastric mucosal protection are classified here. Products containing rebamipide and indicated for dry eye are classified in S1K9.	r201 <u>86</u>
A2C	<u>Out of use</u> OTHER STOMACH DISORDER PREPARATIONS Includes herbal preparations and also plain alginic acid. Combinations of antacids with alginic acid are in A2A1.	R1994 D2018
<u>A2X</u>	<u>OTHER STOMACH DISORDER PRODUCTS</u> <u>Includes herbal preparations and also plain alginic acid. Combinations of antacids with alginic acid are in A2A1.</u>	<u>I2018</u>

A5	CHOLAGOGUES AND HEPATIC PROTECTORS	
A5A	BILE THERAPY AND CHOLAGOGUES	
A5A1	Choleretics and cholekinetics Includes products, plain and in combination, indicated as choleretics and cholekinetics.	
A5A2	Bile stone therapy Includes products indicated for biliary conditions such as stone solvers eg chenodesoxycholic acid, ursodesoxycholic acid. <u>Products containing ursodesoxycholic acid for primary biliary cholangitis are classified here.</u>	<u>r2018</u>
<u>A5A9</u>	<u>Other bile therapy and cholagogues</u> <u>Includes products containing obeticholic acid for primary biliary cholangitis.</u>	<u>I2018</u>
A5B	HEPATIC PROTECTORS, LIPOTROPICS Includes hepatic protectors and combinations, but excludes liver extracts indicated for the treatment of anaemia, which are classified in B3B.	
A5C	CHOLAGOGUE/LIPOTROPIC COMBINATIONS	

A7	ANTIDIARRHOEALS, ORAL ELECTROLYTE REPLACERS AND INTESTINAL ANTI-INFLAMMATORIES	R1993
A7A	INTESTINAL ANTI-INFECTIVE ANTIDIARRHOEALS Includes all products containing one or more intestinal anti-infectives with or without other substances. Sulphonamides and special antibacterials such as polymyxin, neomycin, vancomycin or colistin in oral form, when mainly indicated as antidiarrhoeals are included in this group. Combinations with motility inhibitors, intestinal adsorbents and micro-organisms are also included. <u>Products containing rifaximin for either diarrhoea or hepatic encephalopathy are classified here.</u>	r201 8 7
A7B	INTESTINAL ADSORBENT ANTIDIARRHOEALS Includes products such as kaolin and pectin. Combinations with micro-organisms are also included.	r2011
A7C	Out of use; can be reused.	
A7D	Out of use; can be reused.	

A7E	INFLAMMATORY BOWEL DISORDER PRODUCTS Includes products for inflammatory bowel disorders. Immunosuppressant products used for inflammatory bowel disorders as well as other conditions are classified in L4, for example in L4B (anti-TNF products).	R2017
A7E1	Intestinal aminosalicylate products Includes products containing balsalazide, mesalazine, olsalazine, sulfasalazine and similar aminosalicylates for inflammatory bowel disorders. Products containing aminosalicylates and indicated for rheumatoid arthritis are classified in M1C.	I2017
A7E2	Intestinal corticosteroid products Includes products containing corticosteroids for inflammatory bowel disorders.	I2017
A7E9	Inflammatory bowel disorder products, other Includes other products for inflammatory bowel disorders. Products containing vedolizumab and indicated for inflammatory bowel disease only are classified here. Products containing disodium cromoglicate and indicated for food allergy are classified here.	I2017
A7F	ANTIDIARRHOEAL MICRO-ORGANISMS Includes micro-organisms such as lactobacillus acidophilus which are indicated for the treatment of diarrhoeal disease. Excluded are combinations with other antidiarrhoeals such as anti-infectives, motility inhibitors and intestinal adsorbents.	I1993
A7G	ORAL ELECTROLYTE REPLACERS Oral electrolyte replacers are included in this group where diarrhoeal disease has been indicated. Intravenous preparations are included in K.	I1993
A7H	MOTILITY INHIBITORS Includes narcotic derivatives such as loperamide, diphenoxylate and paregoric. Combinations with intestinal adsorbents and micro-organisms are also included.	I1993
A7X	ALL OTHER ANTIDIARRHOEALS Includes all other antidiarrhoeal products.	I1993

D5	NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS	<u>r2009</u>
	Includes products for psoriasis, hyperkeratosis, ichthyosis, eczema, dermatitis, seborrhoea. Psoralens are classified here when used for inflammatory conditions. Excluded from this class are combinations with antibacterials (D6A), antifungals (D1A) and products specifically indicated in acne (D10A). Combinations with corticosteroids, if not specifically indicated for psoriasis, are classified in D7B. Sulphur baths which contain other substances besides sulphur and are not used for dermatological purposes, are classified in M2A.	
D5A	TOPICAL ANTIPSORIASIS PRODUCTS	R2005
	Includes products, containing substances such as tar, coal tar, ichthammol, dithranol, psoralens, for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing corticosteroids in combination with coal tar for psoriasis are classified here.	
	Includes products consisting of coal tar or calcipotriol, alone or in combination, when indicated for psoriasis.	
D5B	SYSTEMIC ANTIPSORIASIS PRODUCTS	r201 8 7
	Includes products for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing secukinumab or ustekinumab and indicated for psoriasis and also other conditions, eg psoriatic arthritis, are classified in L4C.	
D5X	OTHER NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS	r201 8 6
	Includes nonsteroidal products for inflammatory skin disorders which are not indicated for psoriasis. Specific topical immunomodulators for dermatitis are classified here.	
	Products containing ingenol mebutate or diclofenac gel that are indicated for actinic keratosis are classified here. <u>Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified in L1X8.</u> <u>Products containing topical fluorouracil for actinic keratosis are classified in L1B.</u>	
	<u>Products containing dupilumab for atopic dermatitis are classified here.</u>	

D11	OTHER DERMATOLOGICAL PREPARATIONS	
D11A	OTHER DERMATOLOGICAL PREPARATIONS	R2003 <u>r2018</u>
	Includes medicated shampoos, medicated soaps, scalp lotions (other than in D5A, D1A3, D7B, D8A, D10A). Products for pigmentation disorders, systemic products	

for the treatment of dermatological conditions, anti-corn agents (plasters, tinctures, including products with salicylic acid especially formulated for warts, corns and calluses etc), and hair-restorers are classified in this group.

Products containing finasteride 1mg and for alopecia are classified here. Products containing finasteride 5mg and for BPH are classified in G4C3.

-Products containing extracts of chamomile are classified in D3A.

Psoralens, when used for inflammatory conditions, are classified in D5.

G4	UROLOGICALS	
G4A	URINARY ANTI-INFECTIVES AND ANTISEPTICS	
G4A1	Urinary antibacterials This group includes those products containing an antibacterial where the only indication is for urinary tract infections. Sulphonamides are generally classified in J3 and other antibacterials in J1. All trimethoprim formulations are classified in J1E. Combinations with halogenated or non-halogenated quinolones are classified in G4A2.	r2009
G4A2	Urinary non-halogenated quinolones Includes products containing non-halogenated quinolones which are only indicated for urinary tract infections. Systemic products containing halogenated quinolones (plain) are classified in J1G. Combinations of halogenated or non-halogenated quinolones with other substances (including antibacterials) and indicated for urinary tract infections are classified in G4A2.	R2009
G4A3	Out of use; can be reused from 2010.	D2007
G4A9	Other urinary antiseptics Includes such products as nitrofurantoin and methenamine. Irrigating solutions are classified in Group K.	I2007
G4B	Out of use; can be reused from 2010.	D2007
G4C	-BPH (BENIGN PROSTATIC HYPERTROPHY) PRODUCTS	R2007
G4C1	Out of use	D2012
G4C2	BPH alpha-adrenergic antagonists, plain Includes products containing alpha-adrenergic antagonists, such as alfuzosin, tamsulosin. Products containing terazosin, for BPH or hypertension, are classified here. Products containing doxazosin are classified in C2A2. Products containing indoramin, for BPH or hypertension, are classified in C2A2, or in N2C9 if indicated for migraine.	r2015
G4C3	BPH 5-alpha testosterone reductase inhibitors (5-ARI), plain Includes products containing 5-alpha testosterone reductase inhibitors (5-ARI), such as dutasteride and finasteride. <u>Products containing finasteride 5mg and for BPH are classified here. Products containing finasteride 1mg and for alopecia are classified in D11A.</u>	I2012r <u>2018</u>

J1D	CEPHALOSPORINS	R1997
	Includes all systemic cephalosporins, plain or in combination with other anti-infectives, except in combination with tetracyclines (J1A), chloramphenicols (J1B), broad spectrum penicillins (J1C), products in J1K-P, J1X and sulphonamides (J3A). Combinations with phosphonomycin should, however, be included in this class.	
J1D1	Oral cephalosporins	
	Also included are suppository presentations.	
J1D2	Injectable cephalosporins	
J1E	TRIMETHOPRIM AND SIMILAR FORMULATIONS	R1997
	Includes all systemic trimethoprim formulations, eg Bactrim/Septin, except in combination with tetracyclines (J1A), chloramphenicols (J1B), broad spectrum penicillins (J1C), cephalosporins (J1D) and products in J1K-P, J1X.	
J1F	MACROLIDES AND SIMILAR TYPES	R2003
	Includes all systemic macrolides, including erythromycin, spiramycin, oleandomycin, triacetyloleandomycin, kitasamycin, lincomycin and clindamycin, plain or in combination with other anti-infectives, except in combination with tetracyclines (J1A), chloramphenicols (J1B), broad spectrum penicillins (J1C), cephalosporins (J1D), trimethoprim combinations (J1E), products in J1K-P, J1X and sulphonamides (J3A). Also includes streptogramins.	
J1G	FLUOROQUINOLONES	R2009
	This group includes norfloxacin and similar quinolone antibacterials such as fleroxacin, gatifloxacin, grepafloxacin, ofloxacin, pefloxacin and sparfloxacin. Rosoxacin is also included. Excluded are combinations with tetracyclines (J1A), chloramphenicols (J1B), broad spectrum penicillins (J1C), cephalosporins (J1D), trimethoprim formulations (J1E), macrolides (J1F), aminoglycosides (J1K), carbenicillin and similar (J1L), rifampicin/rifamycin (J1M), other beta-lactam antibacterials (J1P), and the miscellaneous antibacterials of J1X. Includes all systemic products containing halogenated quinolones even if only indicated for urinary tract infections. Combinations of halogenated quinolones with other substances and indicated for urinary tract infections are classified in G4A2.	
J1G1	Oral fluoroquinolones	I1997 <u>2018</u>
	<u>Also included are suppository presentations.</u>	
J1G2	Injectable fluoroquinolones	I1997
<u>J1G9</u>	<u>Other fluoroquinolones</u>	<u>I2018</u>

Includes inhaled forms of levofloxacin. Suppository forms of fluoroquinolones are classified in J1G1.

J4	ANTIMYCOBACTERIALS	R1993
J4A	ANTITUBERCULAR PRODUCTS	r2009
	Includes all specific tubercular preparations as well as streptomycin and dihydrostreptomycin. Other antibacterials such as viomycin and cycloserine which are indicated specifically for tuberculosis are included as well as rifampicin and rifamycin where they are used mostly as tuberculostatics. Where rifampicin and rifamycin are indicated for several conditions, then they are classified in J1M.	
	The definition of ‘single ingredient’ means that only one specific antitubercular drug is present in the product. For example, if a product contains an antitubercular substance and also pyridoxine, this is a single ingredient product and will be classified in J4A1.	
	Kits include various different tablets or forms with different ingredients. Fixed dose products contain the ingredients in one dosage form.	
J4A1	Antituberculars, single ingredient	I2000
J4A2	Antituberculars, kits, four or more ingredients	I2000
J4A3	Antituberculars, kits, three ingredients	I2000
J4A4	Antituberculars, kits, two ingredients	I2000
J4A5	Antituberculars, fixed dose, four or more ingredients	I2000
J4A6	Antituberculars, fixed dose, three ingredients	I2000
J4A7	Antituberculars, fixed dose, two ingredients	I2000
J4A9	Antituberculars, others	I2000
J4B	DRUGS FOR THE TREATMENT OF LEPROSY	rR201 <u>805</u>
	Includes preparations used for the treatment of leprosy (eg aldesulphone, clofazimine, dapsone). <u>Products containing thalidomide for cancer are classified in L1X9 and for erythema nodosum leprosum (ENL) in L4X. Products for both cancer and ENL are classified in L1X9.</u>	

J5	ANTIVIRALS FOR SYSTEMIC USE	R1998 <u>R2018</u>
J5A	Out of use; can be reused from 2001.	D1998
J5B	ANTIVIRALS, <u>OTHER, EXCLUDING ANTI-HIV PRODUCTS</u>	R2010 8
	Includes systemic antivirals <u>for herpes, influenza, viral respiratory conditions, etc.</u> —Excludes topical skin antivirals (D6D), topical ophthalmic antivirals (S1D), and HIV antivirals (J5C), <u>and hepatitis antivirals (J5D).</u> :-	
J5B1	Viral hepatitis products <u>Out of use</u>	2014 <u>D2018</u>
	Includes products for hepatitis B and/or hepatitis C. — Products containing interferons that are indicated for viral hepatitis only are classified here. — Products containing interferons in combination with ribavirin, and only indicated for viral hepatitis, are also classified here. — Includes products containing ribavirin where no indication is specified, except those formulated for inhalation; the latter are classified in J5B5. Single-ingredient products containing tenofovir disoproxil and indicated for either HIV and/or hepatitis are classified in J5C1.	
J5B3	Herpes antivirals	I2008
	Products used against herpes virus infections, including specific systemic forms of products for cytomegalovirus infections (including CMV retinitis), are classified here. Products in topical ophthalmic forms for CMV retinitis are classified in S1D.	
J5B4	Influenza antivirals	I2008
	Includes products indicated specifically for influenza.	
J5B5	Respiratory antivirals excluding influenza products	I2008
	Includes products indicated specifically for respiratory syncytial virus (RSV) infections. Also includes inhalation forms of ribavirin where no indication has been specified.	
J5B9	Antivirals, others	I2008
	Includes products containing lysozyme for viral infections.	

<p>J5C</p>	<p>HIV ANTIVIRALS</p> <p>Includes antiviral products specifically used to treat HIV (human immunodeficiency virus).</p> <p>Combinations of different classes of HIV antivirals are classified in J5C9. Combinations of HIV antivirals from a single class are classified in that relevant specific class, eg a product containing only two nucleoside reverse transcriptase inhibitors is classified in J5C1.</p> <p>Pentamidine isethionate which is used to treat <i>Pneumocystis carinii</i> in AIDS is classified in P1G.</p> <p>Products containing lamivudine as a single ingredient and indicated only for chronic hepatitis B are classified in J5B1.</p>	<p>r2018<u>5</u></p>
<p>J5C1</p>	<p>Nucleoside and nucleotide reverse transcriptase inhibitors</p> <p>Includes abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir disoproxil, zalcitabine, zidovudine. Single-ingredient products containing tenofovir disoproxil and indicated for either HIV and/or hepatitis are classified here.</p> <p><u>Products containing single-ingredient lamivudine or tenofovir alafenamide and for hepatitis B only are classified in J5D2.</u></p>	<p>r201<u>8</u>4</p>
<p>J5C2</p>	<p>Protease inhibitors</p> <p>Includes amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir.</p>	<p>r2011</p>
<p>J5C3</p>	<p>Non-nucleoside reverse transcriptase inhibitors</p> <p>Includes delavirdine, efavirenz, etravirine, nevirapine.</p>	<p>r2011</p>
<p>J5C4</p>	<p>HIV antivirals, entry inhibitors</p> <p>Includes products containing entry inhibitors such as enfuvirtide, maraviroc.</p>	<p>I2011</p>
<p>J5C5</p>	<p>HIV antivirals, integrase inhibitors</p> <p>Includes products containing integrase inhibitors eg dolutegravir, elvitegravir, raltegravir.</p>	<p>I2015</p>

J5C9	<p>Other HIV antivirals, <u>other</u></p> <p>Includes combinations of different classes of HIV antivirals. Combinations of HIV antivirals from a single class are classified in that relevant specific class, eg a product containing only nucleoside reverse transcriptase inhibitors is classified in J5C1.</p> <p>Products containing cobicistat as a single ingredient are classified here. Products containing cobicistat in combination with HIV antivirals are classified in the appropriate class for the antivirals.</p>	r201 8 5
------	--	---------------------

<u>J5D</u>	<u>HEPATITIS ANTIVIRALS</u>	<u>I2018</u>
<u>J5D1</u>	<p><u>Hepatitis antivirals, interferon and ribavirin</u></p> <p><u>Products for hepatitis only containing interferons and/or ribavirin. The products can be for hepatitis B and/or hepatitis C.</u></p> <p><u>Products containing interferons and/or ribavirin in combination with a substance from J5D2 are classified in J5D2. Products containing interferons and/or ribavirin in combination with a substance from J5D3 are classified in J5D3. Products containing interferons (with or without ribavirin) that are for multiple indications are classified in L3B.</u></p>	<u>I2018</u>
<u>J5D2</u>	<p><u>Hepatitis B antivirals</u></p> <p><u>Includes products containing adefovir dipivoxil, clevudine, entecavir, telbivudine, etc.</u></p> <p><u>Products containing lamivudine or tenofovir alafenamide for hepatitis B are classified here; products containing lamivudine or tenofovir alafenamide for HIV are classified in J5C1 or J5C9.</u></p> <p><u>Combinations of these substances with interferons and/or ribavirin are classified here. Products containing interferons and/or ribavirin for hepatitis B are classified in J5D1.</u></p> <p><u>Products containing tenofovir disoproxil only, and indicated for hepatitis, HIV, or for both conditions, are classified in J5C1.</u></p>	<u>I2018</u>
<u>J5D3</u>	<p><u>Hepatitis C antivirals</u></p> <p><u>Includes products containing asunaprevir, beclabuvir, boceprevir, daclatasvir, dasabuvir, elbasvir, glecaprevir, grazoprevir, ledipasvir, narlaprevir, ombitasvir, paritaprevir, pibrentasvir, simeprevir, sofosbuvir, telaprevir, vaniprevir, velpatasvir, voxilaprevir, etc.</u></p> <p><u>Combinations of these substances with each other are also classified here.</u></p> <p><u>Combinations of these substances with ritonavir are classified here.</u></p> <p><u>Combinations of these substances with interferons and/or ribavirin are classified here. Products containing interferons and/or ribavirin for hepatitis C are classified in J5D1.</u></p>	<u>I2018</u>
<u>J5D9</u>	<p><u>Hepatitis antivirals, other</u></p> <p><u>Includes other products for viral hepatitis.</u></p>	<u>I2018</u>

J7	VACCINES	
J7A	Out of use	D2014
J7B	COMBINATIONS OF VACCINES	<u>r2018</u>
	Included are combinations of vaccines for protection against more than one virus and/or bacteria <u>and/or protozoa.-</u>	
J7B1	Combinations with a tetanus component	
J7B2	Combinations with measles and/or mumps	R2007
	MMR vaccine is classified here.	
J7B3	All other combinations	
J7C	Out of use	D2014
J7D	BACTERIAL VACCINES	<u>r2018</u> 4
	Includes <u>separate classes for</u> vaccines against <u>only</u> one bacterial group. For vaccines against a combination of bacteria or viruses, see J7B.	
J7D1	Pneumococcal vaccines	I2014
J7D2	Meningococcal vaccines	I2014
J7D3	Haemophilus B vaccines	I2014
J7D4	Typhoid vaccines	I2014
	Includes vaccines against typhoid and paratyphoid. Vaccines against typhus are classified in J7D9.	
J7D5	Tetanus vaccines	I2014
J7D6	Tuberculosis vaccines	I2014
	BCG vaccine, when used as a general immunostimulant, is classified in L3A9.	
J7D7	Cholera vaccines	I2014
J7D9	All other bacterial vaccines	I2014
	Includes all other vaccines against one bacterial group, eg diphtheria, pertussis, typhus.	

J7E	VIRAL VACCINES	<u>r2018</u> 4
	Includes <u>separate classes for</u> -vaccines against <u>only</u> one viral group. For vaccines against a combination of bacteria or viruses, see J7B.	
J7E1	Influenza vaccines	I2014
J7E2	Varicella vaccines	I2014
J7E3	HPV (human papillomavirus) vaccines	I2014
J7E4	Hepatitis vaccines	I2014
J7E5	Rotavirus vaccines	I2014
J7E9	All other viral vaccines	I2014
	Includes all other vaccines against one viral group, eg Japanese encephalitis, measles, mumps, polio, rubella, rabies, tick-borne encephalitis, yellow fever.	
<u>J7F</u>	<u>PROTOZOAL VACCINES</u>	<u>I2018</u>
	<u>Includes separate classes for vaccines against only one protozoal group. For vaccines against a combination of a protozoal group and/or other organisms, see J7B.</u>	
<u>J7F1</u>	<u>Malaria vaccines</u>	<u>I2018</u>
<u>J7F9</u>	<u>All other protozoal vaccines</u>	<u>I2018</u>
J7X	ALL OTHER VACCINE-LIKE PRODUCTS	r201 <u>86</u>
	Includes products containing infectious agents and/or their derivatives, eg lysates and extracts of bacteria, that are not strictly considered vaccines.	
	Vaccines against malaria are classified here.	

L	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	R1994
L1	ANTINEOPLASTICS Includes all preparations mainly indicated for the treatment of cancers and all packs specifically produced for use in anticancer therapy eg special anticancer packs of antibiotics.	R2003
L1A	ALKYLATING AGENTS Includes nitrogen mustard analogues (eg chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, prednimustine, trofosfamide), ethylene imines (eg altretamine (hexamethylmelamine), carboquone, thiotepa, triaziquone), nitrosoureas (eg bendamustine, carmustine, fotemustine, lomustine, semustine, streptozocin), alkyl sulfonates (eg busulfan, mannosulfan, mitolactol, treosulfan), triazenes and analogues. Dacarbazine is classified in this group.	R2003
L1B	ANTIMETABOLITES Includes folic acid analogues (eg methotrexate), pyrimidine analogues (eg capecitabine, carmofur, cytarabine, fluorouracil, tegafur) and purine analogues (eg fludarabine, mercaptopurine, tioguanine). Methotrexate can also be classified in M1C for rheumatic conditions or in D for dermatological conditions. Products containing topical fluorouracil for actinic keratosis are classified here.	r2016
L1C	PLANT-BASED ANTINEOPLASTICS Includes products that contain plant-derived alkaloids, terpenes, lignans etc, or their derivatives/analogues. Combination products containing substances from two fourth level classes of L1C are classified in the higher level class, eg a combination of a camptothecin with a podophyllotoxin is classified in L1C3.	R2016
L1C1	Vinca alkaloid antineoplastics Includes products containing alkaloids (or their derivatives/analogues) that are derived from <i>Cantharanthus roseus</i> (Madagascan periwinkle), eg vinblastine, vincristine, vindesine, vinflunine, vinorelbine, etc.	I2016
L1C2	Taxane antineoplastics Includes products containing diterpenes (or their derivatives/analogues) that are derived from species of <i>Taxus</i> (yew), eg cabazitaxel, docetaxel, paclitaxel, etc.	I2016

L1C3	<p>Camptothecin antineoplastics</p> <p>Includes products containing alkaloids (or their derivatives/analogues) derived from <i>Camptotheca acuminata</i> (happy tree), eg hydroxycamptothecin, irinotecan, topotecan, etc.</p>	I2016
L1C4	<p>Podophyllotoxin antineoplastics</p> <p>Includes products containing lignans (or their derivatives/analogues) derived from <i>Podophyllum</i> (May apple) species, eg etoposide, mitopodozide, teniposide, etc.</p>	I2106
L1C9	<p>Plant-based antineoplastics, other</p> <p>Includes antineoplastic products containing other plant chemicals (or their derivatives/analogues), eg colchicine derivatives such as demecolcine.</p> <p>Products for cancer containing omacetaxine mepisuccinate are classified here. Products for cancer containing <i>Brucea javanica</i> are classified here.</p> <p>Antineoplastic products that contain dried plant material or unrefined plant extracts are classified in L1X9.</p> <p>Antineoplastic products that are derived from natural sources other than plants, eg from bacteria or fungi, are classified elsewhere.</p>	I2016
L1D	<p>ANTINEOPLASTIC ANTIBIOTICS</p> <p>Includes eg aclarubicin, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, gemtuzumab ozogamicin, idarubicin, mitomycin, mithramycin, mitoxantrone, plicamycin, zorubicin.</p> <p>Products containing mitoxantrone and indicated for both cancer and multiple sclerosis are classified here.</p> <p><u>Products containing gemtuzumab ozogamicin and inotuzumab ozogamicin are classified in L1G.</u></p>	r201 87
L1F	<p>PLATINUM ANTINEOPLASTICS</p> <p>Includes products containing eg carboplatin, cisplatin, oxaliplatin.</p>	I2014

L1G	<p>MONOCLONAL ANTIBODY ANTINEOPLASTICS</p> <p>Includes products containing monoclonal antibodies for neoplasms eg alemtuzumab, bevacizumab, cetuximab, edrecolomab, ibritumomab, rituximab, trastuzumab, <u>etc.</u></p> <p>Products containing alemtuzumab and indicated for cancer only are classified here. Products containing alemtuzumab and indicated for multiple sclerosis are classified in N7A.</p> <p><u>Brentuximab vedotin, Gemtuzumab ozogamicin, ibritumomab tiuxetan, inotuzumab ozogamicin, tocitumomab iodine-131 and trastuzumab emtansine are classified here. is classified in L1D.</u></p> <p>-Antineoplastic monoclonal antibodies against protein kinases are classified here and not in L1H.</p>	r201 <u>87</u>
L1H	<p>PROTEIN KINASE INHIBITOR ANTINEOPLASTICS</p> <p>Includes protein kinase inhibitors for neoplasms, eg axitinib, crizotinib, dasatinib, erlotinib, everolimus, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, regorafenib, <u>ribociclib</u>, ruxolitinib, sorafenib, sunitinib, temsirolimus, vandetanib, vemurafenib, <u>etc.</u></p> <p><u>Products containing both ribociclib and letrozole are classified here.</u></p> <p>Antineoplastic monoclonal antibodies against protein kinases are classified in L1G.</p>	r201 <u>85</u>
<u>L1J</u>	<p><u>PROTEASOME INHIBITOR ANTINEOPLASTICS</u></p> <p><u>Includes products containing proteasome inhibitors for neoplasms, eg bortezomib, carfilzomib, ixazomib, etc.</u></p>	<u>I2018</u>
L1X	<p>ALL OTHER ANTINEOPLASTICS</p>	R201 <u>8</u> 03
L1X1	<p>Adjuvant <u>Alternative</u> preparations for cancer therapy</p> <p>Includes products derived from Viscum (mistletoe).</p>	r 200 <u>3</u> 2018
L1X2	<p>Out of use</p>	D2014
L1X3	<p>Out of use <u>HDAC inhibitor antineoplastics</u></p> <p><u>Includes products containing HDAC inhibitors for neoplasms, eg belinostat, entinostat, panobinostat, romidepsin, tucidinostat, vorinostat, etc.</u></p>	D 2014 <u>I2018</u>
L1X4	<p>Out of use</p>	D2014

<p><u>L1X8</u></p>	<p><u>Photosensitisers for cancer therapy</u></p> <p><u>Includes products containing photosensitisers for use in cancer therapy, eg aminolaevulinic acid, methyl aminolaevulinate, porfimer, talaporfin, temoporfin, etc.</u></p> <p><u>Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified here. Products containing aminolaevulinic acid for use in diagnostic procedures are classified in T1X.</u></p> <p><u>Products containing vertoporphin for macular degeneration are classified in S1P.</u></p>	<p><u>I2018</u></p>
<p>L1X9</p>	<p>All other antineoplastics</p> <p>Includes amsacrine, enzymes, estramustine, gallium nitrate, methylhydralazine, mitotane, procarbazine, substituted urea, tasonermin, <u>vosaroxin</u>. Also includes celecoxib for familial adenomatous polyposis (FAP).</p> <p>Products containing brentuximab vedotin, and for cancer, are classified here.</p> <p><u>Products containing aflibercept for cancer are classified here. Products containing aflibercept for macular degeneration are classified in S1P.</u></p> <p><u>Products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers are classified here. Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified here. Products containing thalidomide for ENL only are in L4X.</u></p> <p><u>CAR T-cell therapies are classified here, for example axicabtagene ciloleucel, tisagenlecleucel-T.</u></p> <p>Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified here.</p>	<p>r201<u>86</u></p>

<p>L2</p>	<p>CYTOSTATIC HORMONE THERAPY</p> <p>Includes all types of hormones used primarily in the treatment of cancers, eg adrenocorticoids, progestogens, oestrogens, anti-oestrogens and androgens.</p>	<p>I1994</p>
<p>L2A</p>	<p>CYTOSTATIC HORMONES</p>	<p>I1994</p>
<p>L2A1</p>	<p>Cytostatic oestrogens</p>	<p>I1994</p>
<p>L2A2</p>	<p>Cytostatic progestogens</p>	<p>I1994</p>
<p>L2A3</p>	<p>Cytostatic gonadotrophin-releasing hormone analogues</p>	<p>R1995</p>

	Buserelin, deslorelin, goserelin, nafarelin, leuprorelin and triptorelin are classified here. When these substances are not used as cytostatics they are classified in H1C.	
L2A9	Other cytostatic hormones Includes substances such as drostanolone, testolactone.	I1994
L2B	CYTOSTATIC HORMONE ANTAGONISTS	I1994
L2B1	Cytostatic anti-oestrogens Includes substances such as tamoxifen, mepitiostane, epitiostanol, toremifene.	R1997
L2B2	Cytostatic anti-androgens Includes substances such as flutamide, nilutamide. Cyproterone acetate (50 mg; injectable forms) is classified here.	I1994
L2B3	Cytostatic aromatase inhibitors Includes aminoglutethamide, anastrozole, exemestane, formestane, letrozole. <u>Products containing both ribociclib and letrozole are classified in L1H.</u>	I2001 <u>2018</u>
L2B9	Other cytostatic hormone antagonists Includes fulvestrant.	R2003

L3	IMMUNOSTIMULATING AGENTS	I1994
L3A	IMMUNOSTIMULATING AGENTS EXCLUDING INTERFERONS	R2004
L3A1	Colony-stimulating factors Includes aneastim, <u>empegfilgrastim</u> , filgrastim, lenograstim, molgramostim, pegfilgrastim, <u>sargramostim</u> .	I2004 <u>2018</u>
L3A9	All other immunostimulating agents excluding interferons Includes cridanimod, glatiramer acetate, interleukin-2, picibanil. BCG vaccine, <i>Corynebacterium parvum</i> , and levamisole are classified here when used as immunostimulants.	r2016
L3B	INTERFERONS Combinations of interferons with ribavirin indicated only for viral hepatitis are classified in J5B1. <u>Products containing interferons (with or without ribavirin) for multiple indications are classified in L3B. Products containing interferons (with or without ribavirin) for hepatitis only are classified in J5D1.</u>	r2009 <u>2018</u>
L3B1	Interferons, alpha	I1994
L3B2	Interferons, beta Products containing beta interferons and indicated for multiple sclerosis only are classified in N7A. Products containing beta interferons and indicated for both multiple sclerosis and other conditions are classified here.	R2017
L3B3	Interferons, gamma	I1994
L3B9	Interferons, non-specified	I1994

L4	IMMUNOSUPPRESSANTS	R2010
L4A	Out of use; can be reused from 2013.	D2010
L4B	ANTI-TNF PRODUCTS Products containing anti-TNF substances are classified here, eg adalimumab, afelimomab, certolizumab pegol, etanercept, golimumab, infliximab. These products can be indicated for multiple conditions, eg rheumatoid arthritis, Crohn's disease, psoriasis.	r201 <u>85</u>

<p>L4C</p>	<p>Products containing apremilast for arthritic conditions are classified in M1C.<u>L4X</u>.</p> <p>INTERLEUKIN INHIBITORS</p> <p>Includes products containing interleukin inhibitors, eg basiliximab, canakinumab, daclizumab, rilonacept.</p> <p>Includes interleukin inhibitors indicated for the treatment of rejection in organ transplants and for auto-inflammatory diseases such as CAPS (cryopyrin-associated periodic syndromes).</p> <p>Products containing tocilizumab or anakinra and indicated for arthritic conditions are classified in M1C. <u>Products containing tocilizumab and indicated for both arthritic conditions and also giant cell arteritis are classified in M1C</u>. Products containing secukinumab or ustekinumab and indicated for psoriasis and also other conditions, eg psoriatic arthritis, are classified here.</p> <p>Products containing daclizumab and indicated for use in kidney transplantation are classified here. Products containing daclizumab and indicated for multiple sclerosis and other conditions are classified in N7A.</p>	<p>r201<u>87</u></p>
<p>L4X</p>	<p>OTHER IMMUNOSUPPRESSANTS</p> <p>Immunosuppressants used in the treatment of rejection in organ transplants are classified here, or in L4C if they contain interleukin inhibitors.</p> <p>Includes eg antilymphocyte and antithymocyte immunoglobulins, azathioprine, cyclosporin, muromonab-cd3, mycophenolate mofetil, tacrolimus – unless classified elsewhere because of a specific indication or formulation. For example, ophthalmic cyclosporin for dry eye is classified in S1K9 and dermatological tacrolimus is classified in D5X.</p> <p>Products for multiple sclerosis are classified in N7A. Products containing natalizumab and indicated for multiple sclerosis and other conditions are classified in N7A.</p> <p>Products containing apremilast are classified here.</p> <p><u>Products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers are classified in L1X9. Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified in L1X9. Products containing thalidomide for erythema nodosum leprosum only are classified here.</u></p> <p>Corticosteroids are not classified here.</p>	<p>r2017r <u>2018</u></p>

M1C	<p>SPECIFIC ANTI-RHEUMATIC AGENTS</p> <p>This class includes abatacept, anakinra, tocilizumab, gold preparations, bucillamine, penicillamine and quinolines (eg oxycinchophen). Includes products containing mesalazine, olsalazine, and sulphasalazine if specifically indicated for rheumatic conditions. Products containing aminosalicylates and used for intestinal inflammatory conditions, are classified in A7E1.</p> <p>Azathioprine is in L4X. Products containing methotrexate for rheumatic conditions are classified here; otherwise methotrexate is classified in LIB or in D.</p> <p>Products containing anti-TNF substances are classified in L4B.</p> <p>Products containing tofacitinib, and indicated for rheumatoid arthritis, are classified here.</p> <p>Products containing interleukin inhibitors and only indicated for arthritic conditions are classified here, eg tocilizumab, anakinra. <u>Products containing tocilizumab and indicated for both arthritis and giant cell arteritis are classified here. Other i-</u>Interleukin inhibitors indicated for multiple conditions including arthritis are classified in L4C.</p> <p>Products containing apremilast are classified in L4X.</p>	r201 8 7
-----	---	---------------------

N7	OTHER CNS DRUGS	R1996
N7A	<p>MULTIPLE SCLEROSIS PRODUCTS</p> <p>Products containing alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, laquinimod, teriflunomide, etc, and indicated for multiple sclerosis only, are classified here.</p> <p>Products containing natalizumab and indicated for multiple sclerosis and other conditions are classified here.</p> <p>Products containing alemtuzumab and indicated for cancer only, are classified in L1G.</p> <p>Products containing daclizumab and indicated for multiple sclerosis and also other conditions are classified here. Products containing daclizumab for use in kidney transplantation only are classified in L4C.</p> <p>Products containing beta interferons and indicated for multiple sclerosis only are classified here. Products containing beta interferons and indicated for both multiple sclerosis and other conditions are classified in L3B2.</p> <p>Products containing mitoxantrone and indicated for both cancer and multiple sclerosis are classified in L1D.</p> <p>Products containing fampridine for improvement in walking in multiple sclerosis are classified in N7X.</p> <p>Products containing other substances, eg corticosteroids, immunosuppressants such as azathioprine, that have multiple uses, are classified elsewhere.</p>	I2017
N7B	<p>ANTISMOKING PRODUCTS</p> <p>Includes products used to stop smoking.</p>	
N7C	<p>ANTIVERTIGO PRODUCTS</p> <p>Includes betahistine, cinnarizine and flunarizine when indicated for vertigo and Meniere's disease.</p>	I1996
N7D	ANTI-ALZHEIMER PRODUCTS	I1998
N7D1	<p>Anti-Alzheimer products, cholinesterase inhibitors</p> <p>Includes eg donepezil, galantamine, rivastigmine and tacrine.</p>	R2003
N7D9	<p>All other anti-Alzheimer products</p> <p>Includes all other products specifically used for Alzheimer's disease.</p>	I1998

N7E	DRUGS USED IN ALCOHOL DEPENDENCE Includes acamprosate, calcium carbimide, disulfiram. Naltrexone when used in alcohol dependence is classified here.	R2002
N7F	DRUGS USED IN OPIOID DEPENDENCE Includes naltrexone, except when used in alcohol dependence (use N7E).	R2002
N7X	ALL OTHER CNS DRUGS Includes parasympathetic agents. Benzodiazepine antagonists such as flumazenil are classified here. Atomoxetine is included in the class. Products containing gabapentin or pregabalin are classified in N3A if indicated for both neuropathic pain and epilepsy. Products containing pilocarpine and indicated for both dry mouth and dry eye are classified here. Products indicated for multiple sclerosis are classified in N7A. Products containing fampridine for improvement in walking in multiple sclerosis are classified here. <u>Products indicated for amyotrophic lateral sclerosis (ALS) are classified here.</u>	R 201 <u>87</u>

P	PARASITOLOGY	
P1	ANTIPROTOZOALS AND ANTHELMINTICS	R2003
P1A	AMOEBICIDES	R2006
	Includes products whose major indication is amoebiasis. Trichomonacides, eg metronidazole, will be classified in G1A or J8B, except when they are used primarily as amoebicides. Products indicated for both trichomoniasis and amoebiasis are classified in G1A1.	
P1B	ANTHELMINTICS, EXCLUDING SCHISTOSOMICIDES	
	In an anthelmintic combination product the anthelmintic component takes precedence over other components.	
P1C	SCHISTOSOMICIDES	
	Products used to treat bilharziasis.	
P1D	ANTI-MALARIALS	r201 86
	If a product contains an antimalarial ingredient and also a second ingredient which is not a specific antimalarial, then this is considered a single-ingredient antimalarial.	
	Vaccines against malaria are classified in J7X <u>J7F1</u>	
P1D1	Anti-malarials, single ingredient	I2000
P1D2	Anti-malarials, multi-ingredient	I2000
P1E	Out of use; can be reused from 2006.	D2003
P1F	Out of use; can be reused	
P1G	OTHER ANTI-PARASITIC AGENTS	R1998
	Includes products for the treatment of leishmaniasis and toxoplasmosis. Pentamidine (used to treat Pneumocystis carinii) is classified here.	

R3L	ANTICHOLINERGICS IN COMBINATION WITH B2-AGONISTS	I2016
R3L1	Short-acting anticholinergic combinations with short-acting B2-agonists, inhalant Includes products containing eg ipratropium bromide with fenoterol, ipratropium bromide with salbutamol, etc	I2016
R3L2	Long-acting anticholinergic combinations with long-acting B2-agonists, inhalant Includes products containing eg aclidinium bromide with formoterol, glycopyrronium bromide with indacaterol, tiotropium bromide with formoterol, tiotropium bromide with olodaterol, umeclidinium bromide with vilanterol, etc. These are known as LAMA/LABA combinations. LAMA/LABA combinations also containing a corticosteroid are classified here.	I2016
R3L8	Anticholinergic combinations with B2-agonists, systemic Includes products containing anticholinergics (short- or long-acting) in combination with B2-agonists (short- or long-acting) for systemic use.	I2016
R3L9	Anticholinergic combinations with B2-agonists, inhalant, other Includes products containing anticholinergics in combination with B2-agonists that cannot be classified in the other R3L classes.	I2016
<u>R3M</u>	<u>INTERLEUKIN INHIBITOR ANTI-ASTHMATICS</u> <u>Includes products containing interleukin inhibitors for asthma, eg benralizumab, mepolizumab, reslizumab, etc.</u>	<u>I2018</u>
R3X	ALL OTHER ANTI-ASTHMA AND COPD PRODUCTS	R2000
R3X1	All other anti-asthma and COPD products, inhalant This subgroup includes anti-asthmatic cigarettes.	R2003
R3X2	All other anti-asthma and COPD products, systemic Includes products containing alpha-1-proteinase inhibitor (alpha-1-antitrypsin). Products containing mepolizumab and indicated for asthma are classified here.	r2018 6

S1P	OCULAR ANTINEOVASCULARISATION PRODUCTS	r2009r 2018
	Includes products indicated specifically for the treatment of wet age-related macular degeneration (AMD) and other ocular conditions where neovascularisation is believed to play a role. Includes <u>aflibercept</u> , anecortave, pegaptanib, ranibizumab, rostoporfin, and verteporfin. Vitamins promoted to prevent AMD are classified in S1M. <u>Products containing aflibercept for cancer are classified in L1X9.</u>	
S1Q	Out of use; can be reused.	
S1R	OPHTHALMIC NON-STEROIDAL ANTI-INFLAMMATORIES	r2017
	Includes non-steroidal anti-inflammatory products for specific ophthalmological conditions. For example, bendazac, diclofenac, flurbiprofen, indomethacin, oxyphenbutazone, piroxicam, pranoprofen, suprofen.	
	Products containing non-steroidal anti-inflammatories in combination with anti-allergics and/or antihistamines are classified in the appropriate S1G subclass.	
S1S	OPHTHALMOLOGICAL SURGICAL AIDS	R2003
	This group comprises drugs used during ophthalmological surgery.	
S1S1	Viscoelastic substances	I1998
	Hyaluronic acid injection or other substances used during surgical procedures on the eye is classified in this group. Hyaluronic acid injection for intra-articular administration (eg 2.5 mg/ampoule) used in the treatment of arthritis is classified in M5X.	
S1S9	Other surgical aids	I1998
	Preparations containing eg enzymes (chymotrypsin, zonolytics) for use in eye surgery; surgical irrigation solutions, eye washes for surgical use only, are classified in this group.	
S1T	OPHTHALMOLOGICAL DIAGNOSTIC AGENTS	I1998
	All diagnostics as far as they do not fit into other classes, diagnostic dyes eg rose bengal, fluorescein.	

T	DIAGNOSTIC AGENTS	I1994
T1	DIAGNOSTIC IMAGING	I1994
T1A	LOW OSMOLAR ANGIO-UROGRAPHY	I1994
T1B	IONIC ANGIO-UROGRAPHY	I1994
T1C	GASTROENTEROGRAPHY	I1994
T1D	CHOLECYSTOGRAPHY AND CHOLANGIOGRAPHY	I1994
T1E	MRI AGENTS Magnetic resonance imaging agents.	I1994
T1F	ULTRASOUND AGENTS	I1994
T1G	RADIODIAGNOSTIC AGENTS Includes radiopharmaceutical products used in diagnosis. Radiopharmaceuticals used as therapeutic agents are classified in V3C.	I2003
T1X	OTHER IMAGING AGENTS <u>Products containing aminolaevulinic acid for cancer therapy are classified in L1X8.</u>	I1994 <u>2018</u>